iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism

Pipeline Updates Financial Overview The balance sheet of ITOS is highly enviable, commanding strong interest income that has helped to offset some of the costs incurred by their rapid expansion into different tumor areas, as well as opening and conducting the GALAXIES-Lung-301 study. They have upwards of 4 years of cash and assets to fund operations, which should be more than enough time to reach a critical milestone, and that's assuming no other momentous developments. I did not touch on the inupadenant pr ...